Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Affitech A/S
Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.
The settlement resolves a total of eight lawsuits between the companies on genetic sequencing technology and alleged antitrust violations.
The preclinical start-up is identifying allosteric binders that can inhibit or activate metabolic proteins. Atavistik will focus on genetically defined diseases then test its candidates in broader populations.
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
- Specialty Pharmaceuticals
- Large Molecule
- Other Names / Subsidiaries
- Actigen Limited